Table 3A. Multiple linear regression analysis of SDAI, DAS28-CRP, and HAQ score at W54. | ||||
---|---|---|---|---|
Factors | B | 95% CI | β | p |
SDAI at W54, R2 = 0.3365 | ||||
Constant | 5.813 | 2.502–9.124 | 0 | 0.0006 |
IFX dosage, mg/kg | −0.562 | −0.983 – −0.142 | −0.123 | 0.0089 |
SDAI at W14 | 0.606 | 0.508–0.704 | 0.569 | < 0.0001 |
DAS28-CRP at W54, R2 = 0.4114 | ||||
Constant | 1.047 | 0.578–1.517 | 0 | < 0.0001 |
IFX dosage, mg/kg | −0.081 | −0.128 – −0.034 | −0.150 | 0.0007 |
DAS28-CRP at W14 | 0.697 | 0.601 – 0.793 | 0.628 | < 0.0001 |
HAQ at W54, R2 = 0.3683 | ||||
Constant | −0.091 | −0.281–0.099 | 0 | 0.3483 |
IFX dosage, mg/kg | −0.015 | −0.035–0.006 | −0.063 | 0.1671 |
HAQ at W0 | 0.353 | 0.253–0.452 | 0.351 | < 0.0001 |
Disease duration, yrs | 0.014 | 0.006–0.022 | 0.160 | 0.0008 |
SDAI at W14 | 0.019 | 0.013–0.024 | 0.345 | < 0.0001 |
HAQ at W54, R2 = 0.3811 | ||||
Constant | −0.401 | −0.623 – −0.180 | 0 | 0.0004 |
IFX dosage, mg/kg | −0.015 | −0.036–0.005 | −0.067 | 0.1403 |
HAQ at W0 | 0.337 | 0.238–0.437 | 0.335 | < 0.0001 |
Disease duration, yrs | 0.014 | 0.006–0.022 | 0.161 | 0.0006 |
DAS28-CRP at W14 | 0.175 | 0.129–0.221 | 0.369 | < 0.0001 |
Table 3B. Multiple logistic regression analysis of achievement of REM/LDA and functional remission at W54. | ||||
Factors | OR | 95% CI | p | |
REM (SDAI) at W54, *R2 = 0.3911 | ||||
IFX dosage, mg/kg | 1.127 | 1.017–1.251 | 0.0218 | |
Disease duration, yrs | 0.947 | 0.904–0.987 | 0.0083 | |
SDAI at W14 | 0.843 | 0.800–0.882 | < 0.0001 | |
LDA (SDAI) at W54, *R2 = 0.3087 | ||||
IFX dosage, mg/kg | 1.118 | 1.018–1.232 | 0.0195 | |
SDAI at W14 | 0.906 | 0.880–0.929 | < 0.0001 | |
REM (DAS28-CRP) at W54, *R2 = 0.3847 | ||||
IFX dosage, mg/kg | 1.156 | 1.050–1.277 | 0.0031 | |
DAS28-CRP at W14 | 0.325 | 0.241–0.424 | < 0.0001 | |
LDA (DAS28-CRP) at W54, *R2 = 0.3757 | ||||
IFX dosage, mg/kg | 1.123 | 1.023–1.235 | 0.0143 | |
DAS28-CRP at W14 | 0.347 | 0.264–0.445 | < 0.0001 | |
Functional remission at W54, *R2 = 0.3805 | ||||
IFX dosage, mg/kg | 1.065 | 0.970–1.172 | 0.1872 | |
HAQ at W0 | 0.242 | 0.147–0.386 | < 0.0001 | |
SDAI at W14 | 0.931 | 0.905–0.955 | < 0.0001 | |
Functional remission at W54, *R2 = 0.4059 | ||||
IFX dosage, mg/kg | 1.078 | 0.980–1.188 | 0.1238 | |
Duration of MTX use, yrs | 0.880 | 0.791–0.973 | 0.0125 | |
HAQ at W0 | 0.241 | 0.145–0.387 | < 0.0001 | |
DAS28-CRP at W14 | 0.506 | 0.395–0.637 | < 0.0001 |
Independent variables were selected using a backward stepwise procedure. Functional remission was defined as HAQ ≤ 0.50.
↵* Nagelkerke R2. REM: clinical remission; LDA: low disease activity; HAQ: Health Assessment Questionnaire; W54: Week 54; SDAI: Simplified Disease Activity Index; DAS28-CRP: 28-joint Disease Activity Score-C-reactive protein; B: nonstandardized coefficients; β: standardized coefficients; R2: explained variance; IFX: infliximab; W14: Week 14; W0: Week 0; MTX: methotrexate.